Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Comparing PACIFIC and GEMSTONE-301

Yi-Long Wu, MD, FACS, Guangdong General Hospital, Guangzhou, China, compares the PACIFIC (NCT02125461) and the GEMSTONE-301 (NCT03728556) clinical trials. Whilst the PACIFIC trial evaluates the efficacy of durvalumab in patients without disease progression after concurrent chemoradiotherapy (CRT), the GEMSTONE-301 trial evaluates sugemalimab in patients without disease progression after both concurrent and sequential CRT. In addition, patients were treated for a period of 12 months in the PACIFIC trial versus 24 months in the Gemstone-301 trial. Importantly, there were differences in the patients enrolled in the study in terms of stages and histology. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Wu reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work.